摘要
目的观察国产厄贝沙坦(irbesartan,吉加)治疗轻、中度原发性高血压的疗效及安全性。方法将60例轻、中度高血压患者随机分为2组,治疗组30例口服国产厄贝沙坦片150mg,每天1次,观察组30例口服进口厄贝沙坦片150mg,每天1次。治疗时间为8周。治疗4周后对舒张压(DBP)≥90mmHg者,药物剂量增至300mg,每天1次。结果经过8周治疗后,治疗组血压由155/97mmHg降至138/86mmHg,对照组血压由155/98mmHg降至136/85mmHg。两组与服药前比较,血压均有明显降低(t值分别为25.94,29.35,P均<0.01),总有效率分别为80.00%和83.33%(χ2=0.004,P>0.05)。两组在治疗过程中均未发生明显不良反应,也无明显心率变化。结论国产与进口厄贝沙坦对轻、中度原发性高血压具有相近的降压效果和安全性。
Aim To compare the curative effect and safety between irbesartan made in China with imported aprovel in treating primary hypertensive patients of grade 1 or 2.Methods 60 patients were divided into 2 groups randomly,irbesartan made in China（Jijia）group（each taking orally 150 mg Jijia per day）and imported irbesartan（aprovel）group（each taking orally 150 mg aprovel per day）.We add irbesartan to 300 mg for diastolic pressure（DBP）≥90 mmHg after 4 weeks.Results After 8 weeks,the pressure in Jijia group dropped from 155/97 mmHg to 138/86 mmHg,from 155/98 mmHg to 136/85 mmHg In Aprovel group（P〈0.01）.Pressure dropped obviously in either group.The ratio of efficacy was 93.33% and 96.67%（P〉0.05）,respectively.There were not severe adverse effects in these two groups.Heart rate had not chang obviously.Conclusion We obtain the same curative effect and safety between Irbesartan made in China with imported aprovel in treating primary hypertensive patients of grade 1 or 2.
出处
《安徽医药》
CAS
2010年第6期720-721,共2页
Anhui Medical and Pharmaceutical Journal
关键词
厄贝沙坦
高血压
疗效
irbesartan
hypertension
effect
